Skip to NavigationSkip to content

Black Swan Analysis Epiomic™ Epidemiology Forecast Report on Thyroid Cancer in 17 Major Markets - ref #BS000026

Black Swan Analysis Epiomic™ Epidemiology Forecast Report on Thyroid Cancer in 17 Major Markets

Thyroid Cancer is a cancer originating from follicular or parafollicular thyroid cells. It is a relatively rare cancer, but the most common of the endocrine system. The main clinical split is between differentiated and undifferentiated tumour types, with the majority being well-differentiated.

This report provides the current incidence population for Thyroid Cancer across 17 Major Markets (USA, France, Germany, Italy, Spain, UK, Brazil, Japan, Canada, Australia, India, Mexico, Turkey, South Africa, Saudi Arabia, Argentina and Russia) split by gender and 5-year age cohort. Along with the current incidence, the report provides an overview of the stages, locations and histopathology of Thyroid Cancer tumours. The report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms of Thyroid Cancer have been quantified and presented alongside the overall incidence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities for Thyroid Cancer include:

  • Familial Adenomatous Polyposis
  • Acromegaly
  • Diabetes
  • Multiple endocrine neoplasia syndromes
    • Sipple syndrome

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information form patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy

  • Able to quantify patient populations in global Thyroid Cancer’s market to target the development of future products, pricing strategies and launch plans.
  • Gain further insight into the incidence of the subdivided types of Thyroid Cancer and identify patient segments with high potential.
  • Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
  • Provide a level of understanding on the impact from specific co-morbid conditions on Thyroid Cancer’s incident population.
  • Examination of the incidence of the different causative gene mutations for Thyroid Cancer.
  • Identify sub-populations within Thyroid Cancer which require treatment.
  • Gain an understanding of the specific markets that have the largest number of Thyroid Cancer patients.

Publisher: Black Swan
Publication Date: December 2015


Please download sample document below for Table of Contents.

The Pharmafile team is happy to provide additional report information on request, prior to purchase.

Price: £ 3,950.00

You need to agree to the Terms and Conditions before placing your order

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches